Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme has reported encouraging findings from a large, multicenter, observational study that investigated the long-term durability of Carticel in patients, who had pain and functional impairment from defects in the articular cartilage of their knee.
Subscribe to our email newsletter
These findings revealed that almost 90% of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost 10 years.
Leanna Caron, vice president and general manager of Genzyme Biosurgery, the division that manufactures and commercializes Carticel, said: “Long-term durability of Carticel had not been evaluated in the US and there was a critical need to determine if Carticel patients experienced sustained improvement. This study demonstrates both the durability and value of Carticel and leads the field to conclude that a vast majority of this patient population maintained improvement, years following their initial procedure.”